Meeting
2016 Gastrointestinal Cancers Symposium
An institutional analysis of gemcitabine and capecitabine for advanced biliary cancer.
Authors
Shipra Gandhi
Roswell Park Cancer Institute, Buffalo, NY
Shipra Gandhi , Emmanuel M. Gabriel , Kristopher Attwood , Wen Wee Ma , Boris W. Kuvshinoff , Steven N. Hochwald , Renuka V. Iyer
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 34, 2016 (suppl 4S; abstr 342)
DOI
10.1200/jco.2016.34.4_suppl.342
Abstract #
342
Poster Bd #
G22
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Real-world assessment of treatment sequencing of patients with advanced biliary tract cancer in a private practice in Rio de Janeiro and São Paulo, Brazil.
First Author: Ligia Carvalho
Poster
2014 ASCO Annual Meeting
Second-line chemotherapy for advanced biliary tract cancer after failure of gemcitabine plus platinum: Results of an AGEO multicenter retrospective study.
First Author: Bertrand Brieau
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Real-world treatments and outcomes of resected biliary tract cancers in British Columbia, Canada.
First Author: Mélina Boutin
Poster
2022 ASCO Annual Meeting
Adjuvant gemcitabine plus cisplatin (GemCis) versus capecitabine (CAP) in patients (pts) with resected lymph node (LN)-positive extrahepatic cholangiocarcinoma (CCA): A multicenter, open-label, randomized, phase 2 study (STAMP).
First Author: Changhoon Yoo